United Kingdom

People: Apellis Pharmaceuticals Inc (APLS.OQ)

APLS.OQ on NASDAQ Stock Exchange Global Select Market

24 May 2019
Change (% chg)

$-0.37 (-1.90%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Deschatelets, Pascal 

Dr. Pascal Deschatelets Ph.D. serves as Co-Founder, Chief Operating Officer of the company. Dr. Deschatelets co-founded Apellis Pharmaceuticals in November 2009 and joined as its Chief Operating Officer. Prior to founding Apellis, Dr. Deschatelets co-founded Potentia Pharmaceuticals, and was its Chief Operating Officer when the company signed a licensing agreement with Alcon in 2009 for Potentia’s ocular drug development program. Apellis acquired all of the assets of Potentia in a transaction that closed in September 2015. Dr. Deschatelets has been engaged in state-of-the-art research in the areas of surface chemistry and organic synthesis for the last 25 years, and was a co-founder of Syntetica Fine Chemicals, a custom chemical synthesis company supporting the pharmaceutical industry. He has extensive experience in nanobiotechnology and in the synthesis of organic molecules and bioconjugates. Dr. Deschatelets received his Ph.D. in organic chemistry from the University of Montreal and his post-doctoral training in the laboratory of Dr. George Whitesides at Harvard University.

Basic Compensation

Total Annual Compensation, USD 399,227
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 461,321
Fiscal Year Total, USD 860,548

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --